Summary of Invention

In one aspect, there is provided the use of a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof in the manufacture of a medicament for use in the treatment of vascular dysfunction associated with impaired endothelium mediated vasodilatation, a reduced endothelial nitric oxide synthase (eNOS) activity, and/or a reduced nitric oxide (NO) bioavailability, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.

In another aspect, there is provided the use of Annexin A5 or a functional analogue or variant thereof in the manufacture of a medicament for use in reducing ischemic pain, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.

In a further aspect, there is provided the use of a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof in the manufacture of a medicament for use in reducing the risk of the onset of acute myocardial infarction (AMI).

In yet a further aspect, there is provided the use of Annexin A5 or a functional analogue or variant thereof in the manufacture of a medicament for use in reducing the risk of the onset of acute myocardial infarction (AMI).

In another aspect, there is provided the use of a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof in the manufacture of a medicament for use in the treatment, prevention, or reduction of risk of onset of a vascular disease that is associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability, wherein the functional analogue or variant of Annexin A5 comprises a protein which is more than 90% identical to human Annexin A5, SEQ ID NO:1.